Korean J Radiol.  2023 Nov;24(11):1102-1113. 10.3348/kjr.2023.0644.

Use of Imaging and Biopsy in Prostate Cancer Diagnosis: A Survey From the Asian Prostate Imaging Working Group

Affiliations
  • 1Department of Medical Imaging and Intervention, New Taipei Municipal Tucheng Hospital, Chang Gung Medical Foundation, New Taipei, Taiwan
  • 2Department of Medical Imaging and Intervention, Linkou Chang Gung Medical Hospital, Taoyuan, Taiwan
  • 3Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
  • 4Department of Radiology, Keio University, School of Medicine, Tokyo, Japan
  • 5Department of Diagnostic Radiology, Tan Tock Seng Hospital, National Health Care Group, Singapore
  • 6Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
  • 7Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
  • 8Department of Radiology, National Defense Medical College, Saitama, Japan
  • 9Department of Radiology, UNM Health Sciences Center, University of New Mexico, Albuquerque, NM, USA
  • 10Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
  • 11Department of Radiology, University of Washington, Seattle, WA, USA
  • 12Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Abstract


Objective
To elucidate the use of radiological studies, including nuclear medicine, and biopsy for the diagnosis and staging of prostate cancer (PCA) in clinical practice and understand the current status of PCA in Asian countries via an international survey.
Materials and Methods
The Asian Prostate Imaging Working Group designed a survey questionnaire with four domains focused on prostate magnetic resonance imaging (MRI), other prostate imaging, prostate biopsy, and PCA backgrounds. The questionnaire was sent to 111 members of professional affiliations in Korea, Japan, Singapore, and Taiwan who were representatives of their working hospitals, and their responses were analyzed.
Results
This survey had a response rate of 97.3% (108/111). The rates of using 3T scanners, antispasmodic agents, laxative drugs, and prostate imaging-reporting and data system reporting for prostate MRI were 21.6%−78.9%, 22.2%−84.2%, 2.3%−26.3%, and 59.5%−100%, respectively. Respondents reported using the highest b-values of 800−2000 sec/mm2 and fields of view of 9−30 cm. The prostate MRI examinations per month ranged from 1 to 600, and they were most commonly indicated for biopsy-naïve patients suspected of PCA in Japan and Singapore and staging of proven PCA in Korea and Taiwan. The most commonly used radiotracers for prostate positron emission tomography are prostate-specific membrane antigen in Singapore and fluorodeoxyglucose in three other countries. The most common timing for prostate MRI was before biopsy (29.9%). Prostate-targeted biopsies were performed in 63.8% of hospitals, usually by MRI-ultrasound fusion approach. The most common presentation was localized PCA in all four countries, and it was usually treated with radical prostatectomy.
Conclusion
This survey showed the diverse technical details and the availability of imaging and biopsy in the evaluation of PCA. This suggests the need for an educational program for Asian radiologists to promote standardized evidence-based imaging approaches for the diagnosis and staging of PCA.

Keyword

Survey; Magnetic resonance imaging; Prostate cancer; Biopsy; Report; PET; PSMA
Full Text Links
  • KJR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr